 SAN DIEGO--BUSINESS WIRE--Ligand Pharmaceuticals Incorporated NASDAQ: LGND announces clinical and regulatory progress by multiple partners utilizing antibodies from its OmniAb discovery platform. Two large multinational pharmaceutical companies with a license to OmniAb have reached clinical-development milestones with their programs. The progress by these companies resulted in a total of 4.5 million in milestone payments being earned by Ligand. In addition, CStone Pharmaceuticals recently 